Monopar Therapeutics (MNPR) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Monopar Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $105K and 6 sold $5.2M of MNPR stock on the open market.
Get emailed when insiders cluster-buy stocks like MNPR
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
MNPR insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $659K | 3 |
| Q3 2026 | — | 0 | $4.2M | 23 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | $105K | 1 | $344K | 2 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Monopar Therapeutics insider reported open-market purchases totaling $105K, while 6 insiders reported sales totaling $5.2M. 26 of 28 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 5SEC | Christopher M StarrDirector | Sell Plan | 4,6318,942 held (−34%) | $78.09 | $362K | +1.1% | — |
| Oct 5SEC | Christopher M StarrDirector | Sell Plan | 2,9705,972 held (−33%) | $78.82 | $234K | +0.2% | — |
| Oct 5SEC | Christopher M StarrDirector | Sell Plan | 7995,173 held (−13%) | $79.67 | $64K | -0.9% | — |
| Sep 28SEC | Chandler RobinsonCEO | Sell Plan | 10,450117,873 held (−8%) | $87.15 | $911K | -9.4% | — |
| Sep 28SEC | Chandler RobinsonCEO | Sell Plan | 9,638108,235 held (−8%) | $87.96 | $848K | -10.2% | — |
| Sep 28SEC | Chandler RobinsonCEO | Sell Plan | 8,36899,867 held (−8%) | $88.97 | $745K | -11.3% | — |
| Sep 28SEC | Chandler RobinsonCEO | Sell Plan | 60099,267 held (−1%) | $89.79 | $54K | -12.1% | — |
| Aug 28SEC | Raymond AndersonDirector | Sell Plan | 1,8025,373 held (−25%) | $113.05 | $204K | -30.2% | — |
| Aug 28SEC | Kim R TsuchimotoDirector | Sell Plan | 1,0981,192 held (−48%) | $111.84 | $123K | -29.4% | — |
| Aug 28SEC | Kim R TsuchimotoDirector | Sell Plan | 7002,290 held (−23%) | $110.65 | $77K | -28.6% | — |
| Aug 28SEC | Raymond AndersonDirector | Sell Plan | 6947,821 held (−8%) | $110.04 | $76K | -28.2% | — |
| Aug 28SEC | Raymond AndersonDirector | Sell Plan | 6467,175 held (−8%) | $111.07 | $72K | -28.9% | — |
| Aug 28SEC | Kim R TsuchimotoDirector | Sell Plan | 602590 held (−51%) | $112.93 | $68K | -30.1% | — |
| Aug 28SEC | Kim R TsuchimotoDirector | Sell Plan | 6152,990 held (−17%) | $109.56 | $67K | -27.9% | — |
| Aug 28SEC | Kim R TsuchimotoDirector | Sell Plan | 590 | $113.84 | $67K | -30.6% | — |
| Aug 28SEC | Kim R TsuchimotoDirector | Sell Plan | 4853,605 held (−12%) | $108.83 | $53K | -27.4% | — |
| Aug 27SEC | Raymond AndersonDirector | Sell Plan | 1,80223,751 held (−7%) | $113.05 | $204K | -30.2% | — |
| Aug 27SEC | Kim R TsuchimotoDirector | Sell Plan | 1,0988,588 held (−11%) | $111.84 | $123K | -29.4% | — |
| Aug 27SEC | Kim R TsuchimotoDirector | Sell Plan | 7009,686 held (−7%) | $110.65 | $77K | -28.6% | — |
| Aug 27SEC | Raymond AndersonDirector | Sell Plan | 69426,169 held (−3%) | $110.04 | $76K | -28.2% | — |
| Aug 27SEC | Raymond AndersonDirector | Sell Plan | 64625,523 held (−2%) | $110.07 | $71K | -28.3% | — |
| Aug 27SEC | Kim R TsuchimotoDirector | Sell Plan | 6027,986 held (−7%) | $112.93 | $68K | -30.1% | — |
| Aug 27SEC | Kim R TsuchimotoDirector | Sell Plan | 61510,386 held (−6%) | $109.56 | $67K | -27.9% | — |
| Aug 27SEC | Kim R TsuchimotoDirector | Sell Plan | 5907,396 held (−7%) | $113.84 | $67K | -30.6% | — |
| Aug 27SEC | Kim R TsuchimotoDirector | Sell Plan | 48511,001 held (−4%) | $108.83 | $53K | -27.4% | — |
| Aug 27SEC | Patrice RiouxActing Chief Medical Officer | Sell Plan | 15,065 held (−0%) | $111.26 | $111 | -29.0% | — |
| Dec 29SEC | Quan Anh VuCFO | Buy | 1,500new position | $69.95 | $105K | +12.9% | — |
| Dec 19SEC | Arthur J KlausnerDirector | Sell | 4,6609,223 held (−34%) | $67.06 | $312K | +17.7% | — |
| Dec 19SEC | Arthur J KlausnerDirector | Sell | 4618,762 held (−5%) | $68.09 | $31K | +16.0% | — |
Insiders at Monopar Therapeutics
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Chandler RobinsonCEO | — | $2.6M | Sep 28, 2026 | — |
| Kim R TsuchimotoDirector | — | $911K | Aug 28, 2026 | — |
| Raymond AndersonDirector | — | $703K | Aug 28, 2026 | — |
| Christopher M StarrDirector | — | $659K | Oct 5, 2026 | — |
| Arthur J KlausnerDirector | — | $344K | Dec 19, 2025 | — |
| Quan Anh VuCFO | $105K | — | Dec 29, 2025 | — |
| Patrice RiouxActing Chief Medical Officer | — | $111 | Aug 27, 2026 | — |
MNPR stock: common questions
Are Monopar Therapeutics insiders buying MNPR stock?
In the past 12 months, 1 insiders reported open-market purchases of MNPR worth $105K. The latest was CFO Quan Anh Vu bought $105K of MNPR at $69.95 — first open-market purchase in our records; opens a new position.
Are Monopar Therapeutics insiders selling MNPR stock?
6 insiders reported sales worth $5.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is MNPR's 52-week range?
Over the past year MNPR has traded between $50.12 and $123.84. It last closed at $78.96 on Oct 9, 2026.